# Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

> **NCT00045526** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (estimated)

## Conditions studied

- Adenocarcinoma of the Esophagus
- Adenocarcinoma of the Gastroesophageal Junction
- Recurrent Esophageal Cancer
- Squamous Cell Carcinoma of the Esophagus
- Stage III Esophageal Cancer
- Stage IV Esophageal Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00045526
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2007-02
- **Final completion:** —
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045526, "Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00045526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*